Background: Monthly intravenous immunoglobulin (IVIG) and weekly subcutaneous immuno-
INTRODUCTION
Immunoglobulin G (IgG) replacement therapy is the mainstay of treatment in many primary immunodeficiency diseases (PIDD) associated with humoral immune defects, including common variable immunodeficiency disease (CVID), congenital hypogammaglobulinemia and agammaglobulinemia.
1 While intravenous immunoglobulin (IVIG) was the most common mode of replacement in 1980-1990, subcutaneous IgG (SCIG) administration has become increasingly common in clinical practice since the 1990s.
2 Both IVIG and SCIG have been regarded therapeutically equivalent (have same efficacy for prevention of bacterial infections) in patients with PIDD 3, 4 and choice of the use of IVIG vs. SCIG has to take into account the comparative advantages and disadvantages between these for a given patient. For example, advantages of SCIG being fewer systemic adverse events, 4 ,5 improved quality of life 5, 6 and stable IgG levels 6, 7 and disadvantages being more local infusion sites reactions accounting for adverse events [8] [9] [10] [11] and requirement of frequent infusions (weekly vs. monthly).
4,5
It is unclear if there are universally accepted threshold IgG levels that correlate with adequate protection from severe infections. Serum IgG concentrations !500 mg/dl following IgG therapy have been recommended for adequate protection from serious infections in PIDDs. [12] [13] [14] The serum IgG trough level, defined as concentration preceding the next dose of immunoglobulin (Ig) infusion, has been regarded as an important guide to therapy. 15 Several recent studies have shown higher serum IgG concentrations, resulting from higher intravenous IgG and subcutaneous IgG dosing regimens, associated with infection prevention and decreasing infection-associated morbidity. 13, 16, 17 Data from earlier studies have endorsed IgG trough level of 500 mg/dl as an appropriate initial minimum target for infection prevention in PIDD. 14, 18 However, subsequent clinical evidence has prompted recommendations for higher target levels of >800 mg/dl 19 and 650-1000 mg/dl 20 in recent clinical guidelines. Due to inconsistent trough levels, a recommendation to individualize treatment plans based on symptoms and infections has been proposed. 3 Studies have also suggested no significant differences in efficacy or adverse reaction rates between subcutaneous and intravenous immunoglobulin treatment.
4
In this systematic review and meta-analysis, we sought to compare IVIG vs. SCIG in PIDD patients and its effects on IgG trough levels, the overall incidence of infection and serious infections (including pneumonia) to help guide clinicians in appropriate clinical decision making.
METHODS
The preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement as recommended by the Cochrane Collaboration for reporting systematic reviews 21 was used ( Fig. 1 ). This systematic review included studies published from Jan 1, 2010, to May 30, 2018 . A metaanalysis on studies earlier than 2010 was already carried out by Orange et al.;
13 we focused our review on studies after 2010 to cover newer studies since the recent advancements in the treatment of these diseases. Searches of MEDLINE, EMBASE, Cochrane Library, and Scopus databases were carried out to identify eligible studies. A combination of subject headings (MeSH, EMTREE) and text words was used for each concept. Search terms and synonyms for "immunologic deficiency" and "immunoglobulins" were combined in the search with "AND" using Boolean logic. Synonyms for immune deficiency included "immunologic deficiency syndromes", "common variable immunodeficiency", "dysgammaglobulinemia", "agammaglobulinemia", "hypogammaglobulinemia" (the text words allowed for both American and British spellings). Synonyms for immunoglobulins included "immunoglobulins", "intravenous", "subcutaneous" abbreviations of IVIG, SQIG, as well as specific brand names such as Carimune, Gammagard, and subject headings which included specific routes of injection such as immunoglobulins/ intravenous or immunoglobulins/subcutaneous were included.
The eligibility criteria for this systematic review were (1) human subjects with a diagnosis of PIDD undergoing IgG treatment; (2) reported outcomes comparing IVIG, SCIG, or different dosage/forms of IVIG/SCIG; (3) Documented IgG trough level; (4) Studies showing an outcome of interest (overall infection, pneumonia/serious infection, or hospitalization rates). Studies without documented therapy studies not reporting any outcome of interest or definitions of those outcomes, and studies without a comparator were excluded from our analysis. Conference extracts were excluded. The language was restricted to English. Study abstracts were screened by two investigators (PS and AJ), full-text articles were reviewed for those that fulfilled eligibility criteria and irrelevant articles were excluded. Disputes were settled with mutual agreement. To minimize data duplication as a result of multiple reporting, we compared articles from the same investigator. Relevant data were extracted by two investigators (PS and AJ) and checked by another (PK).
From each study, we extracted and tabulated details on the study source, design, patient with PIDD, type of PIDD included, mean age in years, percentage of female patients, percentage of CVID patients, the region of study, the total population of study and duration of the study (Table 1) . Furthermore, we extracted the details on treatment, including the type of treatment IgG used, comparison group, dosing protocol, IgG trough level, pneumonia rate, overall infection rate, days of hospitalizations, days missed from school/work and adverse events per patient-year (Table 2 ).
Study quality was formally evaluated by two investigators (PS and AD) using a modified Newcastle-Ottawa Quality Assessment Scale 22 for observational studies. Any discrepancies were resolved by a third author (PK) (Supplementary File 1). The outcomes from individual studies were calculated with RevMan, version 5.3 (Cochrane Collaboration, Oxford, United Kingdom). The Inverse-Variance method was used to compare the IVIG and SCIG trough levels. Risk Ratios (RRs) and 95% confidence intervals (CIs) were estimated using a random-effects method to control the heterogeneity as their assumption accounts for the presence of variability among the studies. 23 The I 2 statistic was used to estimate the percentage of heterogeneity among the studies. I 2 values < 30% were considered a low heterogeneity, 30%-60% as moderate, and >60% as high. 24 Peto odds ratio was used when the event rate was <1%. DerSimonian and Laird random-effects method was used to pool the difference of IgG trough levels along with random-effect meta-regression to evaluate infection incidence per 100 mg/dl IgG trough increase through IVIG and SCIG. A p-value of <0.05 was used as a level of significance. Publication bias was assessed by visual assessment of funnel plots (Supplementary File 2).
RESULTS
Our study included 24 studies that met our eligibility criteria, of which 21 were prospective, 2 were ambispective and 1 was a retrospective study (Table 1) . Twelve studies were conducted in the United States, 10 in European countries (2 with the US), 4 in Canada (with the US), 2 in Argentina, 1 in Japan and Turkey each, and a multinational study by the US along with Chile and Israel. Treatment IgG products used and study durations were included. The mean patient age was 23.8 years in 24 studies, with 10 studies including those <18 years and 14 including those >18 years of age. Seven studies had more than 50% females, but males comprised the majority of the patient population overall. Disease types resulting in PIDD by the study are shown in Supplemental whereas, SCIG dose was given weekly. Trough levels calculated in studies varied in terms of timing, with most of the levels drawn prior to the next IVIG and SCIG infusion. After reviewing the quality of studies, 11 studies were compared in the meta-analysis for trough levels as depicted in the forest plot (Fig. 2) . Inclusion criteria of the studies stipulated documented diagnosis of PIDD requiring IgG therapy with a stable dose and trough level. However, in one study done by Borte et al., patients above 2 years of age with PIDD requiring 0.3-1 g/kg IgG for ! 3 months with serum IgG trough 5 g/l only were included.
Patients with chronic infections with Hepatitis B, C or HIV, on antibiotics, abnormal liver and renal function tests, severe neutropenia, thrombotic episodes, malignancy, currently receiving immunosuppression, pregnant or nursing were excluded in most studies. Reported details on criteria for pneumonia diagnosis during the course of treatment with IVIG and SCIG therapy were limited, with some studies reporting the diagnosis based on history, chest X-ray, physical exam and need for hospitalization. Pneumonia was also sometimes reported as a "serious infection" separating it from the overall infections diagnosed during the treatment period. However, due to the low number of pneumonia diagnoses reported in the studies, regression analysis was focused on overall infections and serious infections. The annual rate of infection per patient was calculated, when not provided, for statistical analysis. Days of hospitalization, days missed from school and work, adverse events from the IVIG and SCIG therapy were reviewed and included if reported (Table 2 ).
Among the total 24 studies, 13 with IVIG therapy and 11 with SCIG therapy were reviewed owing to the availability of data required for comparative study and meta-analysis. Eleven studies which compared IVIG and SCIG therapy were included in the initial meta-analysis. Higher mean trough level attainment was evident in the SCIG group as compared to IVIG with a mean difference of 75.43 , with moderate heterogeneity (I 2 ¼ 45%) (Fig. 2) .
Among 6 studies comparing IVIG vs. SCIG in terms of the incidence of infection, the difference in risk of overall infections (Risk difference ¼ 1.58, 95% CI: 0.75-3.33, p ¼ 0.23, I
2 ¼ 96%) or serious infections was not statistically significant (Peto odds ratio ¼ 1.94, 95% CI: 0.59-6.32, (p ¼ 0.59, I ¼ 0%), but a clinically relevant difference could not be ruled out (Fig. 3a and b) .
Random-effects meta-regression analysis was used to analyze the increase in IgG trough level with a concomitant increase in IVIG and SCIG dose. No notable linear relationship with dosedependent trough level was seen with either IVIG or SCIG therapy ( Fig. 4a and b) . However, across the studies included for regression analysis of IVIG and SCIG trough vs. infection incidence (Fig. 5a and b) , each additional 100 mg/dl trough attained through SCIG was associated with a reduction in pneumonia incidence rate, as displayed in Fig. 5b . No significant trend was apparent within the IVIG trough range as depicted in Fig. 5a . 
DISCUSSION
Our study shows higher IgG trough levels in patients on SCIG vs. IVIG therapy. Among the 11 studies included in our meta-analysis of IVIG vs. SCIG trough level, consistently higher trough levels were observed with SCIG. A study done by Chapel et al. had also reported higher trough level in patients on SCIG therapy compared to IVIG, but doses differing as per infusion centers, differences in route of administration with no statistical evaluation of achieved serum IgG level make the comparison difficult.
4 Similar findings were reported by Bonagura et al. as well. 25 These findings may be due to the fact that pharmacokinetics of IgG tends to differ when smaller doses are given more frequently as compared to large boluses given on a monthly basis. SCIG therapy has been noted to have lower peaks and higher IgG troughs. A total IgG dose divided into three or four equal portions in weekly intervals is expected to have less variation and fluctuations of IgG trough level, approximately 900 mg/dl difference in peak and trough level after IVIG infusion in comparison to 100 mg/dl difference of the same after SCIG infusion. 26 Another study by Radinski advocated that frequent SCIG dosing allows better maintenance of consistent serum IgG levels.
27 Although our study favored higher level of IgG trough on SCIG therapy, increment in the level per dose increase did not have a linear correlation, and a similar finding was observed with IVIG therapy as well. This could have resulted from the variation of timing in measuring trough levels in different studies. Although the measurement of IgG trough level was done prior to infusion in most studies, some did not mention the exact timing of level drawn. Whether trough levels should be used as a guide for treatment remains controversial. Data from earlier studies have endorsed IgG trough level of 500 mg/dl as an appropriate initial minimum target for infection prevention in PIDD. 18 However, subsequent clinical evidence has prompted recommendations for higher target levels of >800 mg/dl 19 and 650-1000 mg/dl 20 in recent clinical guidelines. Due to inconsistent trough levels, preference for individualized treatment plan based on symptoms and infection prevention are considered.
3 More studies are required to ascertain pharmacokinetic parameters such as maximal concentration in serum (C max ), the time necessary to reach concentration after complete infusion (T max ) and volume of distribution.
Similarly, a clear positive association of higher trough levels with lower infection rates was seen with SCIG in our meta-regression. Infection incidence rate with trough 800-900 mg/dl at 4.97 (CI 4.3-5.8) precipitously decreased to 1.85 (CI 0.14-3.6) and with trough level of 1200 þ mg/dl which was statistically significant at p ¼ 0.03. This relation, however, was not seen with IVIG therapy. Although we included 24 studies in our systematic review, we could only include 11 studies in our metaanalysis owing to lack of patient-level data. An earlier meta-analysis done by Orange et al. had also noted a significant reduction in pneumonia incidence (incidence rate ratio -0.726, CI 0.658-0.801), with a 27% reduction in pneumonia incidence for each 100 mg/dl increment in trough IgG. 13 While this study's analysis was limited to pneumonia incidence, authors did suggest the advantages of higher trough levels benefitting overall infection prevention as well. Comparison of overall or serious infections between IVIG vs. SCIG was not significantly different, however, a clinically significant difference cannot be ruled out due to a low number of patients and wide confidence interval seen.
The primary strength of this study is that it includes a large group of studies to quantify the relationship of infection rate and IgG trough levels in PIDD patients, along with the relationship of dose vs. trough level in IVIG as well as SCIG modes of treatment. Our results may have been confounded by a focused presentation on the efficacy of SCIG product, as most study trials were developed by pharmaceutical companies. Another caveat could be an effect seen by several studies in the past which noted serum IgG levels to rise continuously for months when previously untreated or under-treated patients received SCIG therapy. 26, 28 Although the study includes studies done in several countries with large patient data, most studies are cohort studies, which limits the overall strength of evidence.
Our study did not show a significant difference in overall infections or serious infections with IVIG vs. SCIG, but a clinically significant difference Volume 12, No. 10, Month 2019 cannot be ruled out. Based on our observation, weekly SCIG attained a higher trough level in comparison to monthly IVIG. Higher SCIG troughs were associated with lower infection rates, while IVIG troughs demonstrated no relationship. More randomized controlled trials are required to look at the effect of dosing with serum IgG trough levels, and more importantly its effect on infection prevention.
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